Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06325930 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6
A Phase 1 study, sponsored by Rivus Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT06325930: Completed Phase 1 study, sponsored by Rivus Pharmaceuticals.
NCT06325930 is a Phase 1 study that has completed, run by Rivus Pharmaceuticals. The registered enrollment target is 8 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06325930, a Phase 1 study, has completed, sponsored by Rivus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered approximately 15 minutes prior to dosing.
Primary Outcome
(i.e., the cumulative excretion of total 14C in urine and feces), of \[14C\]-HU6 following a single dose of \[14C\]-HU6, in healthy, adult male subjects
Interventions
- DRUG [14C]-HU6
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2024-03-26 |
| Est. Completion | 2024-05-07 |
| Phase | Phase 1 |
What the finished NCT06325930 record still lists
NCT06325930 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C]-HU6 is the first listed.
NCT06325930 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06325930 about?
NCT06325930 is a clinical study titled "A Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-HU6". This is a single-center, non-randomized, open-label Phase 1 study to characterize the absorption, metabolism, excretion, mass balance, pharmacokinetics (PK), safety and tolerability of HU6 following administration of a single dose of \[14C\]-HU6 in a fed state with a standard meal administered appro...
What is the current status of trial NCT06325930?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2024-03-26. Estimated completion is 2024-05-07.
What interventions are being tested in trial NCT06325930?
The interventions under investigation include: [14C]-HU6 (DRUG).
Who is sponsoring clinical trial NCT06325930?
This trial is sponsored by Rivus Pharmaceuticals, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06325930's enrollment target sits among peer trials
8 1959th of 2000 higher than 29 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI